In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36745891.
- Also identified by DOI 10.7326/J22-0118.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eikelboom JW, Jolly SS, Belley-Cote EP, et al. <b>Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.</b> Lancet Respir Med. 2022;10:1160-8. 36228639.
Medical subject headings
- Aspirin
- COVID-19